Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus
Neffe, J.; Gilmore, S. A.; Tam, D.; Cheung, T. L.; Snyder, C.; Farand, J.; Dick, R.; Matles, M.; Feng, J. Y.; Ramirez, R.; Li, L.; Yu, H.; Xu, Y.; Barnes, D.; Czerwieniec, G.; Brendza, K. M.; Appleby, T. C.; Birkus, G.; Willkom, M.; Kobayashi, T.; Paoli, E.; Labelle, M.; Boesen, T.; Tay, C. H.; Delaney, W. E.; Notte, G. T.; Feierbach, B.
Show abstract
Chronic hepatitis B (CHB) is a global health care challenge and a major cause of liver disease. To find new therapeutic avenues with a potential to functionally cure chronic Hepatitis B virus (HBV) infection, we performed a focused screen of epigenetic modifiers to identify replication inhibitors. From this work we identified isonicotinic acid inhibitors of the histone lysine demethylase 5 (KDM5) with potent anti-HBV activity. To enhance the cellular permeability and liver accumulation of the most potent KDM5 inhibitor identified (GS-080) an ester prodrug was developed (GS-5801) that resulted in improved bioavailability and liver exposure as well as an increased H3K4me3:H3 ratio on chromatin. GS-5801 treatment of HBV-infected primary human hepatocytes inhibited HBV replication and antigen levels. Evaluation of GS-5801 antiviral activity in a humanized mouse model of HBV infection, however, did not result in antiviral efficacy, despite achieving pharmacodynamic levels of H3K4me3:H3 predicted to be efficacious from the in vitro model. Here we discuss potential reasons for the disconnect between in vitro and in vivo efficacy, which highlight the translational difficulties of epigenetic targets for viral diseases.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production 95%
- Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580 94%
- The kinesin KIF4 mediates HBV/HDV entry through regulation of surface NTCP localization and can be targeted by RXR agonists in vitro. 94%
Similar papers in this journal
- The Dual-Specificity Kinase Dyrk1A Interacts With The Hepatitis B Virus Genome And Regulates The Production Of Viral RNA 94%
- Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo 93%
- Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out 93%
Similar papers in this journal
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 93%
- Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery 93%
- mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models 92%
Similar papers in this journal
- Human liver organoids; a patient-derived primary model for HBV Infection and Related Hepatocellular Carcinoma 95%
- Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis 94%
- Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy 94%
Similar papers in this journal
- Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs 94%
- A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses 93%
- Proof of concept: Targeted protein degradation of the stress granules component G3BP1 as an antiviral strategy against norovirus infection 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.